Please assess the completion status of the following clinical trial:

Trial Title: P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Metastatic neuroendocrine tumors that are considered well or moderately differentiated (or low to intermediate grade). Patients with poorly differentiated neuroendocrine carcinomas or small cell carcinomas are excluded from the study.~* Elevated urine 5-hydroxyindoleacetic acid (5-HIAA)~* More than 2 bowel-movements per day OR more than 4 flushing episodes per week on average~* Patient currently on octreotide LAR 30mg every 3 or 4 weeks (for at least 3 cycles prior to screening)~* Age ≥ 18 years~* Minimum of four weeks since any major surgery, liver-directed therapy (embolization, etc.) or systemic cancer treatment other than octreotide LAR~* Eastern Cooperative Oncology Group (ECOG) performance status ≤2~* Life expectancy \> 12 weeks~* Reliable contraception should be maintained throughout the study and for 3 months after study drug discontinuation.~* Signed informed consent to participate in the study must be obtained from patients after they have been fully informed of the nature and potential risks by the investigator (or his/her designee) with the aid of written information.~Exclusion Criteria:~* Known hypersensitivity to somatostatin analogues~* Patients with poorly differentiated neuroendocrine cancers~* Patients with liver cirrhosis~* Patients receiving hemodialysis or peritoneal dialysis~* Patients with cachexia who, in the opinion of the investigator, may have difficulty tolerating intramuscular injection~* Patients with symptomatic cholelithiasis or biliary events within past five years (who have not undergone cholecystectomy)~* Patients with recent history (within 5 years) of pancreatitis~* Patients with uncontrolled diabetes (HgA1c \>8.0 despite adequate therapy)~* Women of child-bearing potential, UNLESS they are using two birth control methods~* Women who are pregnant or lactating~* HIV positive patients~* History of sustained ventricular tachycardia, ventricular fibrillation, advanced heart block, idiopathic syncope thought to be related to ventricular arrhythmia, or congenital long QT syndrome~* Risk factors for Torsades de Pointes such as cardiac failure, clinically significant/symptomatic bradycardia~* Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study~* History of noncompliance to medical regimens or unwillingness to comply with the protocol~* Patients who were unable to tolerate or did not benefit from above-label dose octreotide (\>30mg) in the past~* Concomitant use of other cancer treatments or carcinoid syndrome treatments (whether standard or experimental). Patients should discontinue any concomitant cancer medications more than two weeks prior to screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Octreotide Long-acting Release (LAR) (Type: EXPERIMENTAL): Octreotide LAR will be administered at a dose of 60 mg intramuscularly (IM) every 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).